CoChat

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing

Open access

Published version of a preprint

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: To define dominant molecular and cellular features associated with PD-1/PD-L1 blockade resistance in metastatic urothelial cancer. Experimental Design: We pursued an unbiased approach using bulk RNA sequencing data from two clinical trials to discover (IMvigor 210) and validate (CheckMate 275) pretreatment molecular features associated with resistance to PD-1/PD-L1 blockade in metastatic urothelial cancer. We then generated single-cell RNA sequencing (scRNA-seq) data from muscle-invasive bladder cancer specimens to dissect the cellular composition underlying the identified gene signatures. Results: We identified an adaptive immune response gene signature associated with response and a protumorigenic inflammation gene signature associated with resistance to PD-1/PD-L1 blockade. The adaptive immune response:protumorigenic inflammation signature expression ratio, coined the 2IR score, best correlated with clinical outcomes, and was externally validated. Mapping these bulk gene signatures onto scRNA-seq data uncovered their underlying cellular diversity, with prominent expression of the protumorigenic inflammation signature by myeloid phagocytic cells. However, heterogeneity in expression of adaptive immune and protumorigenic inflammation genes was observed among single myeloid phagocytic cells, quantified as the myeloid single cell immune:protumorigenic inflammation ratio (Msc2IR) score. Single myeloid phagocytic cells with low Msc2IR scores demonstrated upregulation of proinflammatory cytokines/chemokines and downregulation of antigen presentation genes, were unrelated to M1 versus M2 polarization, and were enriched in pretreatment blood samples from patients with PD-L1 blockade–resistant metastatic urothelial cancer. Conclusions: The balance of adaptive immunity and protumorigenic inflammation in individual tumor microenvironments is associated with PD-1/PD-L1 resistance in urothelial cancer with the latter linked to a proinflammatory cellular state of myeloid phagocytic cells detectable in tumor and blood. See related commentary by Drake, p. 4139

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-4574

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 106

Metadata

Authors
Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., Wiklund, P., Oh, W. K., Szabo, P. M., Wind-Rotolo, M., Unsal-Kacmaz, K., Yao, X., Schadt, E., Sharma, P., Bhardwaj, N., Zhu, J., & Galsky, M. D.
Affiliations
  • Sema4 (United States) (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • 5Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Tisch Cancer Institute (US)
  • 8Bristol-Myers Squibb, Princeton, New Jersey.
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Zhu, Jun
  • Galsky, Matthew D.
Venue
Clinical Cancer Research
Published
2021-04-09
Volume
27
Issue
15
Pages
4287-4300
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3141281714
Cited by
97
References
63
Citations by year
2026: 16 · 2025: 19 · 2024: 18 · 2023: 22 · 2022: 15 · 2021: 7
FWCI
5.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Clinical Cancer Research (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
NIH Loan Repayment Program (CA196521)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
Keywords
metastatic urothelial carcinoma, muscle-invasive bladder cancer, adaptive immune response, tumor microenvironment, antigen presentation genes, immune checkpoint inhibitors, single-cell RNA sequencing, bulk RNA-seq
MeSH terms
Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Humans, Sequence Analysis, RNA, Drug Resistance, Neoplasm, Myeloid Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-4574
The paper
Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., Wiklund, P., Oh, W. K., Szabo, P. M., Wind-Rotolo, M., Unsal-Kacmaz, K., Yao, X., Schadt, E., Sharma, P., Bhardwaj, N., . . . Galsky, M. D. (2021). Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-4574

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.